PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

ECMO treatment: Critically ill patients were treated with ECMO while receiving antimicrobial therapy

Study summary

Extracorporeal membrane pulmonary oxygenation (ECMO) may provide partial or complete support for organ replacement in patients with severe cardiopulmonary failure, buying time for further management of the primary disease. However, ECMO may significantly alter the pharmacokinetic and pharmacodynamic profiles of critically ill patients, affecting the safety and efficacy of drug therapy. This prospective observational study aims to investigate the impact of ECMO treatment on the pharmacokinetics and pharmacodynamics of antimicrobial drugs in critically ill adult patients. Investigators intend to establish a Population Pharmacokinetic (POP PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) model by prospectively collecting blood samples from patients and relevant treatment data. The primary objective is to quantitatively characterize the pharmacokinetic profiles of critically ill patients undergoing ECMO support and provide model-based recommendations for drug regimens tailored to critically ill patients.

Eligibility

Primary outcome measure(s)

• Blood drug concentration — Samples were taken in the first 72 hours after administration according to the sampling schedule
  Plasma drug concentration
• Pharmacokinetic parameter — 24 hours after administration
  Area under the plasma concentration-time curve（AUC）
• Pharmacokinetic parameter — 12 hours after administration
  Peak Plasma Concentration (Cmax)

Trial sites (1)

More The Third Xiangya Hospital of Central South University trials in China

Other trials for the same condition